Invetx agreed to be acquired by Dechra for up to $520 million in total consideration.
A veterinary therapeutics company focused on biopharmaceuticals that bring the best of human biotechnology to animal health
A veterinary therapeutics company focused on biopharmaceuticals that bring the best of human biotechnology to animal health. Invetx develops novel protein-based therapeutics, particularly monoclonal antibodies, for companion animals.